Results 171 to 180 of about 70,987 (344)

Regulation of Immune Checkpoints: From Molecular Mechanisms to Clinical Therapies

MedComm, Volume 7, Issue 6, June 2026.
Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment by unleashing antitumor immunity. This review comprehensively examines the molecular mechanisms underlying key immune checkpoints—including PD‐1/PD‐L1, CTLA‐4, and TIM‐3—and their clinical applications.
Qintao Ge, Liu Yu, Jiahe Lu, Aihetaimujiang Anwaier, Xiyue Xiao, Yonghao Chen, Dingwei Ye, Hailiang Zhang, Wenhao Xu, Wenbin Dai   +9 more
wiley   +1 more source

Analysis of CacyBP/SIP, ERK1/2, and p38 Expression in Low‐ and High‐Grade Papillary Urothelial Carcinoma

Cancer Medicine
Background Papillary urothelial carcinoma (transitional cell carcinoma) is one of the most common malignant tumors of the urinary tract. Urothelial carcinomas are classified into muscle‐invasive and non‐muscle‐invasive types.
Natalia Domian, Grzegorz Młynarczyk, Irena Kasacka   +2 more
doaj   +1 more source

On why cancer cells require a great amount of glucose

Quantitative Biology, Volume 14, Issue 2, June 2026.
Abstract The traditional thinking has been that cancer cells require a great amount of glucose to support their rapid growth, but the reality may be different. We have previously demonstrated that all cancer cells in The Cancer Genome Atlas harbor persistent Fenton reactions in their cytosol, which generate OH− ${\text{OH}}^{-}$ and ultimately kill the
Xuechen Mu, Aoran Liu, Rui Shi, Long Xu, Zhenyu Huang, Ye Zhang, Ying Xu   +6 more
wiley   +1 more source

Personalized Cancer Vaccines in the Clinical Trial Pipeline

Asia-Pacific Journal of Clinical Oncology, Volume 22, Issue 3, Page 362-368, June 2026.
ABSTRACT Aim To present an overview of personalized cancer vaccines currently undergoing clinical development, aiming to enhance awareness and promote collaboration among academic, commercial researchers, and non‐profit communities. Methods A dataset of 78 clinical trials for personalized cancer vaccines was generated using ClinicalTrials.gov database ...
Liudmila Iamukova, Elena Alferova
wiley   +1 more source

Proteogenomics of different urothelial bladder cancer stages reveals distinct molecular features for papillary cancer and carcinoma in situ [PDF]

, 2023
Zhenmei Yao, Ning Xu, Guoguo Shang, Haixing Wang, Hui Tao, Yunzhi Wang, Zhaoyu Qin, Subei Tan, Jinwen Feng, Jiajun Zhu, Fahan Ma, Sha Tian, Qiao Zhang, Yuanyuan Qu, Jun Hou, Jianming Guo, Jian‐Yuan Zhao, Yingyong Hou, Chen Ding   +18 more
openalex   +1 more source

A minor high‐grade component in non‐invasive papillary urothelial carcinoma is not associated with a more indolent behaviour

Histopathology, Volume 88, Issue 7, Page 1430-1442, June 2026.
Non‐invasive papillary urothelial carcinomas with minor high‐grade component are not associated with a more indolent behavior and should likely be regarded as high‐grade carcinomas. Aims The latest WHO edition proposed using a cut‐off of ≥5% high‐grade component (%HGc) as a criterion to label non‐invasive papillary urothelial carcinomas as high‐grade ...
Mina S. Farag, Neda Oghbaei, Jaffar Hussain, André Lametti, Wassim Kassouf, Fadi Brimo   +5 more
wiley   +1 more source

Expression of GLUT4 and FAP in urothelial bladder carcinoma: correlation with angiogenesis and clinicopathological characteristics [PDF]

, 2022
Marwa A. Abd El-Azeem, Mona A. Ali, Safinaz H. El-Shorbagy   +2 more
openalex   +1 more source

Sarcomatoid urothelial carcinoma of the bladder

Asian Journal of Surgery
Cungeng Fan, Binglin Lai
openaire   +3 more sources

PAX8‐positive conventional urothelial carcinomas of the urinary bladder and their distinct molecular profiles – A clinicopathologic study of 101 consecutive cases with next‐generation sequencing in 20 cases

Histopathology, Volume 88, Issue 7, Page 1315-1323, June 2026.
PAX8 expression in urothelial carcinoma was investigated in 101 consecutive transurethral resections of the urinary bladder. PAX8 was positive in 10% of cases, with targeted molecular testing of these cases revealing universal TERT promoter mutations and frequent alterations in TSC1, NOTCH1 and WT1. Aims PAX8 immunohistochemistry (IHC) is often used to
Sarah Mae Lammert, Wendy Luo, Allen C Zhu, Peng Wang, Tatjana Antic, Jung Woo Kwon   +5 more
wiley   +1 more source

Avelumab First-Line Maintenance for Advanced Urothelial Carcinoma: Results From the JAVELIN Bladder 100 Trial After ≥2 Years of Follow-Up [PDF]

, 2023
Thomas Powles, Se Hoon Park, Claudia Caserta, Begoña P. Valderrama, Howard Gurney, Anders Ullén, Yohann Loriot, Srikala S. Sridhar, Cora N. Sternberg, Joaquim Bellmunt, Jeanny B. Aragon‐Ching, Jing Wang, Bo Huang, Robert J Laliberte, Alessandra di Pietro, Petros Grivas   +15 more
openalex   +1 more source